Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1998-10-30
2000-02-01
Stockton, Laura L.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514416, 514417, 514309, 514372, 548451, 548472, 548478, 548209, 546141, A61K 3140, C07D20946, C07D20948, C07D20956
Patent
active
060203587
ABSTRACT:
Phenethylsulfones substituted in the position .alpha. to the phenyl group with a 1-oxoisoindoline or 1,3-dioxoisoindoline group reduce the levels of TNF.alpha. in a mammal. Typical embodiments are 2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-aminoisoindoline- 1,3-dione and 2-[1-(3-cyclopentyloxy-4-methoxyphenyl)-2-methylsulfonylethyl]isoindoline- 1,3-dione.
REFERENCES:
patent: 4173652 (1979-11-01), Bruins et al.
patent: 4556673 (1985-12-01), Anderson et al.
patent: 4820828 (1989-04-01), Demers et al.
patent: 5658940 (1997-08-01), Muller et al.
Corral, Laura G., et al. (Jul. 1996), "Selection of Novel Analogs of Thalidomide with Enhanced Tumor Necrosis Factor alpha Inhibitory Activity", Molecular Medicine, vol. 2, No. 4, pp. 506-515, Jul. 1996.
A. De, U. et al., (Feb. 1975), "Possible Antineoplastic Agents I", Journal of Pharmaceutical Sciences, vol. 64(2), pp. 262-266.
Barnes, P.J., (1995) "Cyclic nucleotides and phosphodiesterases and airway function", Eur Respir. J. vol. 8, pp. 457-462.
Bazzoni, Flavia, et al., (Jun. 26, 1996), "The Tumor Necrosis Factor Ligand And Receptor Families", Seminars in Medicine of the Beth Israel Hospital, Boston, Flier, Jeffrey S., et al, Ed., vol. 334, No. 26, pp. 1717-1725.
Burnouf, Catherine, et al., (1998), "Chapter 10: Phosphodiesterases 4 Inhibitors", Annual Reports in Medicinal Chemistry, Doherty, Ed., vol. 33, pp. 91-109.
Buu-Ho, Nouyen P. et al., (Mar. 1970), "Synthesis and Pharmacological Properties of Substituted Cinnamohydroxamic Acids", JMC, vol. 13(2), pp. 211-213.
Badger, Alison M. et al., (Oct. 1997), "Advances in antiarthritic therapeutics", DDT, vol. 2, No. 10, pp. 427-435.
Beutler, Bruce et al., (1993), "Tumor Necrosis Factor in the pathogenesis of infectious diseases", Critical Care Medicine, vol. 21, No. 10, pp. S423-S435.
deBrito, FB et al., (1997) "Type 4 Phosphodiesterase Inhibitors and their Potential in the Treatment of Inflammatory Disease", Emerging Drugs, vol. 2, Chapter Twelve pp. 249-268.
Denis, L.J., et al., (1997) "Matrix Metalloproteinase Inhibitors: Present Achievements and Future Prospects", Investigational New Drugs, vol. 15, pp. 175-185.
Eger, K. et al., (1990), "Synthesis, Central Nervous System Activity and Teratogenicity of a Homothalidomide", Arzneim-Forsch/Drug Res, vol. 40(II), No. 10 pp. 1073-1975.0.
Friderichs, Von E., (1982), "Untersuchungen zum ZNS-Wirkprofil von Thalidomid-Analoga", Arzhelm-Forsch./Drug Res., vol. 32(1), No. 6, pp. 613-620.
Hart, David J. et al., (1983) "Preparation of Primary Amines and 2-Azetidinones via N-Trimethylsilyl Imines", J. Org. Chem., vol. 48, pp. 289-294.
Hughes, Bernadette, et al., (Mar. 1997) "PDE 4 inhibitors: the use of molecular cloning in the design and development of novel drugs", DDT, vol. 2, No. 3, pp. 89-101.
Kleinman, Edward F., et al., (1998), "Striking Effect of Hydroxamic Acid Substitution on the Phosphodiesterase Type 4 (PDE4) and TNF .alpha. Inhibitory Activity of Two Series of Rolipram Analogues: Implications for a New Active Site Model of PDE4.", J. Med. Chem., vol. 41, pp. 266-270.
Lombardo, Louis J., (Sep. 1995), "Anti-Inflammatory & Anti-Allergy Agents", Current Pharmaceutical Design, Weichman, Barry M., Ed., vol. 1, No. 2, pp. 255-268.
Lee, John C. et al., (1995), "Low-Molecular-Weight TNF Biosynthesis Inhibitors: Strategies and Prospectives", Circulatory Shock, vol. 44, pp. 97-103.
Levy, Daniel E., et al., (1998), Matrix Metalloproteinase Inhibitors: A Structure-Activity Study, J. Med Chem., vol. 41, pp. 199-223.
Muller, Thomas et al., (Aug. 1996) "Subtypes of the type 4 cAMP phosphodiesterases: structure, regulation and selective inhibition", TIPS, vol. 17, pp. 294-298.
Marriott, J. Blake, (1997), "TNF-.alpha. antagonists: monoclonal antibodies, soluble receptors, thalidomide and other novel approaches", Exp. Opin. Invest. Drugs, vol. 6(8), pp. 1105-1108.
Muller, George W., et al, (1998), "Thalidomide Analogs and PDE4 Inhibition", Bioorganic & Medicinal Chemistry Letters, vol. 8, pp. 2669-2674.
Muller, George W., et al. (1996), "Structural Modifications of Thalidomide Produce Analogs with Enhanced Tumor Necrosis Factor Inhibitory Activity", Journal of Medicinal Chemistry, vol. 39, No. 17, pp. 3238-3240.
Natchus, Michael G., et al., (1998), "Design and Synthesis of Conformationally-Constrained MMP Inhibitors", Bioorganic & Medicinal Chemistry Letters, vol. 8, pp. 2077-2080.
Naafs, B., et al., (Mar. 1985), "Thalidomide Therapy, An Open Trial", International Journal of Dermatology, vol. 24(2), pp. 131-134.
Palfreyman, Malcolm N., (1995) "Phosphodiesterase type IV inhibitors as Anti-Inflammatory agents", Drugs of the Future, vol. 30(8), pp. 793-804.
Palacios, Jose Maria, et al., (1995), "Second Messenger Systems as Targets for New Therapeutic Agents: Focus on Selective Phosphodiesterase Inhibitors", Il Farmaco, vol. 50(12), pp. 819-827.
Summers, James B., et al, (1998), "Matrix Metalloproteinase Inhibitors and Cancer", Annual Reports In Medicinal Chemistry, vol. 33, pp. 131-140.
Steinman, Douglas H. et al, (1998), "The Design, Synthesis, and Structure-Activity Relationships of a Series of Macrocyclic MMP Inhibitors", Bioorganic & Medicinal Chemistry Letters, vol. 8, pp. 2087-2092.
Strieter, Robert M. et al., (1993), "Role of tumor necrosis factor-.alpha. in disease states and inflammation", Critical Care Medicine, vol. 21, No. 10, pp. S447-S463.
Torphy, Theodore J. et al., (May 1993) "Novel Phosphodiesterase Inhibitors for the Therapy of Asthma", DN&P vol. 6(4), pp. 203-214.
Torphy, Theodore J. et al., (1998) "Phosphodiesterase Isozymes, Molecular Targets for Novel Antiasthma Agents", Am J. Resp. Crit. Care Med., vol. 157, pp. 351-370.
Torphy, Theodore J., (1997), "Phosphodiesterase Inhibitors", Asthma, Barnes, P.J. et al., pp. 1755-1773.
Teixeira, Mauro M. et al., (May 1997) "Phosphodiesterase (PDE)4 inhibitors:anti-inflammatory drugs of the future", TIPS, vol. 18, pp. 164-170.
Tracey, Kevin J. et al, (1993), "Tumor Necrosis Factor, Other Cytokines and Disease", Annu. Rev. Cell Biol. vol. 9, pp. 317-343.
Tanaka, Kuntyoshi, et al., (1983), "Syntheses and Anti-Inflammatory and Analgesic Activities of Hydroxamic Acids and Acid Hydrazides", Chem. Pharm. Bull, vol. 31(8), pp. 2810-2819.
Wojtowicz-Praga, Slawomir M., et al., (1997), "Matrix Metalloproteinase Inhibitors", Investigational New Drugs, vol. 15, pp. 61-75.
Yu, Anita E., et al., (Sep. 1997), "Matrix Metalloproteinases, Novel Targets for Directed Cancer Therapy", Drugs & Aging, vol. 11(3), pp. 229-244.
Man Hon-Wah
Muller George W.
Celgene Corporation
Stockton Laura L.
LandOfFree
Substituted phenethylsulfones and method of reducing TNF.alpha. does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Substituted phenethylsulfones and method of reducing TNF.alpha. , we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Substituted phenethylsulfones and method of reducing TNF.alpha. will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-937898